USD 30.23 billion growth expected in Non-Small Cell Lung Cancer Drugs Market | Evolving Opportunities with AbbVie Inc. and Amgen Inc. | Technavio

Download a Sample Report Now to understand the scope of the report.

The market is driven by the increasing prevalence and incidence of non-small cell lung cancer. In addition, the introduction and approval of combination therapies is anticipated to boost the growth of the non-small cell lung cancer drugs market.

The rise in risk factors such as cigarette smoking, secondary smoking, air pollution, and occupational exposure have increased the prevalence of lung cancer globally. It is also one of the leading causes of cancer deaths globally. According to a study, in 2021, there were approximately 235,760 new cases of lung cancer in the US, and an estimated 131,880 people were expected to die of this disease. The prevalence of conditions such as non-small cell lung cancer is also on the rise in developing countries, especially in Asian countries owing to rapid industrial development and sub-urbanization. Many such factors are increasing the demand for drugs to cure the condition, which is driving the growth of the market.

Learn about other factors impacting the market growth. Request a Sample Report

Major Vendors in Non-small Cell Lung Cancer Drugs Market:

The global non-small cell lung cancer drugs market is concentrated. The market is characterized by the presence of generic drug manufacturers and pharmaceutical giants that offer drugs for the treatment of non-small cell lung cancer. Vendors are competing based on factors such as operational costs, innovations, price, and product quality. Vendors are also focusing on achieving a competitive edge by introducing new technologies and increasing their margins in response to changing market conditions in end-user facilities. Technavio identifies the following as the dominant players in the market.

• AbbVie Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca Plc
• Bayer AG
• BeiGene Ltd.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Innovent Biologics Inc.
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Merck and Co. Inc.
• Merck KGaA
• Novartis AG
• Ono Pharmaceutical Co. Ltd.
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.

Non-small Cell Lung Cancer Drugs Market: Segmentation Analysis

The global non-small cell lung cancer drugs market is segmented by product (biologics, small molecule targeted therapy, and chemotherapy) and geography (North America, Europe, Asia, and the Rest of the World (ROW)).

Non-small Cell Lung Cancer Drugs Market: Product Outlook (Revenue, USD Billion, 2021-2026)

• Biologics - size and forecast 2021-2026
• Small molecule targeted therapy - size and forecast 2021-2026
• Chemotherapy - size and forecast 2021-2026

The biologics segment generated maximum revenue in the market in 2021. The segment is driven by the increased prevalence of non-small cell lung cancer and the availability of biologics to treat the disease. The market growth in the segment will be significant during the forecast period.

Non-small Cell Lung Cancer Drugs Market: Geography Outlook (Revenue, USD Billion, 2021-2026)

• North America - size and forecast 2021-2026
• Europe - size and forecast 2021-2026
• Asia - size and forecast 2021-2026
• Rest of World (ROW) - size and forecast 2021-2026

North America will offer maximum growth opportunities for market players. The region currently holds 39% of the global market share. The high prevalence of non-small cell lung cancer in the region is prompting government organizations to raise awareness through lung cancer screening programs such as National Comprehensive Cancer Control Program (NCCCP) and National Tobacco Control Program. In addition, the approval of immune checkpoint inhibitors with chemotherapy will drive market growth in the region during the forecast period.

Gain access to vendor profiles and identify key revenue generating segments by purchasing our full report. View Our Sample Report Before Purchasing

Related Reports:

Cancer Biologics Market by Product and Geography - Forecast and Analysis 2022-2026

Liver Cancer Drugs Market by Type and Geography - Forecast and Analysis 2022-2026

Table of Contents:

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers
• Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026

• 4.3 Bargaining power of suppliers
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product

• 5.1 Market segments
• Exhibit 24: Chart on Product - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Product - Market share 2021-2026 (%)

• 5.2 Comparison by Product
• Exhibit 26: Chart on Comparison by Product
• Exhibit 27: Data Table on Comparison by Product

• 5.3 Biologics - Market size and forecast 2021-2026
• Exhibit 28: Chart on Biologics - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Biologics - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Biologics - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Biologics - Year-over-year growth 2021-2026 (%)

• 5.4 Small molecule targeted therapy - Market size and forecast 2021-2026
• Exhibit 32: Chart on Small molecule targeted therapy - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Small molecule targeted therapy - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Small molecule targeted therapy - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Small molecule targeted therapy - Year-over-year growth 2021-2026 (%)

• 5.5 Chemotherapy - Market size and forecast 2021-2026
• Exhibit 36: Chart on Chemotherapy - Market size and forecast 2021-2026 ($ million)
• Exhibit 37: Data Table on Chemotherapy - Market size and forecast 2021-2026 ($ million)
• Exhibit 38: Chart on Chemotherapy - Year-over-year growth 2021-2026 (%)
• Exhibit 39: Data Table on Chemotherapy - Year-over-year growth 2021-2026 (%)

• 5.6 Market opportunity by Product
• Exhibit 40: Market opportunity by Product ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview
• Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 42: Chart on Market share by geography 2021-2026 (%)
• Exhibit 43: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison
• Exhibit 44: Chart on Geographic comparison
• Exhibit 45: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Canada - Market size and forecast 2021-2026
• Exhibit 66: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.9 Germany - Market size and forecast 2021-2026
• Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.10 China - Market size and forecast 2021-2026
• Exhibit 74: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.11 UK - Market size and forecast 2021-2026
• Exhibit 78: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 79: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 80: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 81: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography
• Exhibit 82: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges
• Exhibit 83: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• Exhibit 84: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption
• Exhibit 85: Overview on factors of disruption

• 9.4 Industry risks
• Exhibit 86: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 87: Vendors covered

• 10.2 Market positioning of vendors
• Exhibit 88: Matrix on vendor position and classification

• 10.3 Amgen Inc.
• Exhibit 89: Amgen Inc. - Overview
• Exhibit 90: Amgen Inc. - Business segments
• Exhibit 91: Amgen Inc. - Key offerings
• Exhibit 92: Amgen Inc. - Segment focus

• 10.4 AstraZeneca Plc
• Exhibit 93: AstraZeneca Plc - Overview
• Exhibit 94: AstraZeneca Plc - Key news
• Exhibit 95: AstraZeneca Plc - Key offerings

• 10.5 Boehringer Ingelheim International GmbH
• Exhibit 96: Boehringer Ingelheim International GmbH - Overview
• Exhibit 97: Boehringer Ingelheim International GmbH - Business segments
• Exhibit 98: Boehringer Ingelheim International GmbH - Key news
• Exhibit 99: Boehringer Ingelheim International GmbH - Key offerings
• Exhibit 100: Boehringer Ingelheim International GmbH - Segment focus

• 10.6 Bristol-Myers Squibb Co.
• Exhibit 101: Bristol-Myers Squibb Co. - Overview
• Exhibit 102: Bristol-Myers Squibb Co. - Product / Service
• Exhibit 103: Bristol-Myers Squibb Co. - Key offerings

• 10.7 Eli Lilly and Co.
• Exhibit 104: Eli Lilly and Co. - Overview
• Exhibit 105: Eli Lilly and Co. - Business segments
• Exhibit 106: Eli Lilly and Co. - Key offerings
• Exhibit 107: Eli Lilly and Co. - Segment focus

• 10.8 F. Hoffmann La Roche Ltd.
• Exhibit 108: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 109: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 110: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 111: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 112: F. Hoffmann La Roche Ltd. - Segment focus

• 10.9 Merck KGaA
• Exhibit 113: Merck KGaA - Overview
• Exhibit 114: Merck KGaA - Business segments
• Exhibit 115: Merck KGaA - Key news
• Exhibit 116: Merck KGaA - Key offerings
• Exhibit 117: Merck KGaA - Segment focus

• 10.10 Ono Pharmaceutical Co. Ltd.
• Exhibit 118: Ono Pharmaceutical Co. Ltd. - Overview
• Exhibit 119: Ono Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 120: Ono Pharmaceutical Co. Ltd. - Key offerings

• 10.11 Pfizer Inc.
• Exhibit 121: Pfizer Inc. - Overview
• Exhibit 122: Pfizer Inc. - Business segments
• Exhibit 123: Pfizer Inc. - Key news
• Exhibit 124: Pfizer Inc. - Key offerings
• Exhibit 125: Pfizer Inc. - Segment focus

• 10.12 Takeda Pharmaceutical Co. Ltd.
• Exhibit 126: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibit 127: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 128: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibit 129: Takeda Pharmaceutical Co. Ltd. - Key offerings

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist
• Exhibit 130: Inclusions checklist
• Exhibit 131: Exclusions checklist

• 11.3 Currency conversion rates for US$
• Exhibit 132: Currency conversion rates for US$

• 11.4 Research methodology
• Exhibit 133: Research methodology
• Exhibit 134: Validation techniques employed for market sizing
• Exhibit 135: Information sources

• 11.5 List of abbreviations
• Exhibit 136: List of abbreviations

About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio